Evaluating Lecanemab Eligibility for Patients in Skilled Nursing Facilities With Alzheimer Disease or Mild Cognitive Impairment

Approximately 3.9 million older adults receive care in US skilled nursing facilities (SNFs) yearly, and nearly half are diagnosed with Alzheimer's disease (AD) or other dementias.1 Lecanemab (Leqembi) is the first anti-amyloid monoclonal antibody to receive full US Food and Drug Administration (FDA) approval to slow AD progression.2 SNF residents with AD comprise a unique population of multimorbid adults for consideration of disease-modifying therapies as they include persons receiving short-term rehabilitation after a hospitalization, and patients requiring long-term nursing and medical services.